Helix BioPharma Corp. saw a significant drop in its stock price this week amid various financial developments.
Helix BioPharma Corp. (HBP.TO) experienced a notable decline in its stock price, closing at C$1.45 on Monday, down 6.75% for the day and 17.84% for the week. This downturn comes amidst a backdrop of recent financial activities, including private placements and strategic agreements aimed at raising capital for its therapeutic programs.
Advertisement
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$110.75M
52W high
$5.40
52W low
$1.10
1W change
-19.44%
Beta
-0.27
Analyst Price Targets
Based on analyst covering HBP
Wall Street analysts forecast HBP stock price to rise 72.4% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+72.4% Upside
Current Price
C$1.45
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
77.9%
Annualized
90-Day Vol
67.1%
Annualized
Trend (90d)
-14.2%
Annualized drift
90d Mean
C$1.38
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$1.43 | C$1.09 โ C$1.87 |
| 60 trading days | C$1.40 | C$0.96 โ C$2.05 |
| 90 trading days | C$1.38 | C$0.87 โ C$2.20 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should be aware of the recent price volatility in Helix BioPharma's stock, particularly in light of the company's ongoing efforts to secure funding and advance its projects. The market's reaction may reflect broader concerns regarding the biotech sector's capital environment.
C$1.45 Close Amid Significant Volume
Helix BioPharma's stock traded 3,836 shares on Monday, which is 2.08 times its 20-day average volume of 2,984 shares, indicating heightened interest from investors despite the price decline.
Bull case
Analysts have set an average target of C$2.50 for Helix BioPharma, suggesting a potential upside of 72.4%. This positive outlook is based on the company's strategic initiatives and the potential for growth in its therapeutic programs.
Bear case
Despite the optimistic analyst outlook, Helix BioPharma has faced significant losses and a tough market environment. The company has a profit margin of 0.0%, and its return on equity is notably negative at -50.0%, indicating ongoing financial challenges.
Recent Price Action
Helix BioPharma Corp. closed at C$1.45 on Monday, reflecting a decline of 6.75% for the day. Over the past week, the stock has dropped 17.84%, and its year-to-date performance shows a significant decrease of 36.67%. This decline appears to be influenced by a combination of internal financial developments and broader market sentiment.
Company News and Developments
Advertisement
There has been no major news from Helix BioPharma Corp. this week; however, the company has been active in securing capital through various avenues. Recently, Helix announced the closing of a private placement of common shares, raising CAD$3,000,000 to support its working capital needs. Additionally, the company signed a capital-raising agreement with Kerentech Consulting Ltd. to assist in a bridge financing round aimed at advancing its therapeutic programs.
Technical Picture
The current technical indicators for Helix BioPharma show the stock trading below both its 50-day moving average of C$1.64 and its 200-day moving average of C$1.85, indicating a bearish trend. The stock's 52-week range is between C$1.10 and C$5.40, with the current price representing only 8% of this range. With a beta of -0.27, Helix's stock exhibits lower volatility compared to the broader market.
Insider Activity
No recent insider activity has been reported for Helix BioPharma Corp. This lack of insider transactions may suggest that company executives are currently refraining from buying or selling shares, potentially reflecting their confidence in the company's future prospects.
Price Action Summary
As of the last close, Helix BioPharma Corp. stock is priced at C$1.45, down 6.75% for the day. Investors should monitor upcoming developments closely, as the company's efforts to raise capital and advance its projects could impact future stock performance.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
